Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new experimental medication called tulisokibart to see if it can help reduce the joint pain, swelling, and skin symptoms of psoriatic arthritis. About 140 adults will participate, with some receiving the new medication at different doses and others receiving a placebo (a fake pill). After 16 weeks, researchers will measure how well the medication worked and then continue monitoring participants for up to 2 more years.
Psoriatic arthritis is a serious condition that damages joints and causes significant pain and disability. While some treatments exist, many patients either don't respond well to current options or can't tolerate them, so researchers are testing this new medication as a potential alternative.
You likely qualify if…
You likely don't qualify if…
Participants will be randomly assigned to receive either the new medication at one of three different doses or a placebo pill. For the first 16 weeks, you'll take your assigned treatment and visit the clinic regularly so researchers can check how well it's working and monitor for side effects. After 16 weeks, those who received placebo will switch to the active medication. The study then continues for up to 2 more years, with participants visiting the clinic periodically to track how they're doing.
AI-generated summary from trial data · May 5, 2026 · Not medical advice
United States